BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25465375)

  • 1. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
    Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
    Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
    Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
    Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
    Beppu T; Emi Y; Tokunaga S; Oki E; Shirabe K; Ueno S; Kuramoto M; Kabashima A; Takahashi I; Samura H; Eguchi S; Akagi Y; Natsugoe S; Ogata Y; Kakeji Y; Baba H; Maehara Y;
    Anticancer Res; 2014 Nov; 34(11):6655-62. PubMed ID: 25368271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
    Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].
    Kaibori M; Iwamoto S; Ishizaki M; Matsui K; Saito T; Yoshioka K; Kwon AH
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2579-82. PubMed ID: 20009458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
    Kanemitsu Y; Kato T; Shimizu Y; Inaba Y; Shimada Y; Nakamura K; Sato A; Moriya Y;
    Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
    J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
    Takahashi T; Shibata Y; Tojima Y; Tsuboi K; Sakamoto E; Kunieda K; Matsuoka H; Suzumura K; Sato M; Naganuma T; Sakamoto J; Morita S; Kondo K
    Int J Clin Oncol; 2013 Apr; 18(2):335-42. PubMed ID: 22383023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
    Nagayama S; Hasegawa S; Hida K; Kawada K; Hatano E; Nakamura K; Seo S; Taura K; Yasuchika K; Matsuo T; Zaima M; Kanazawa A; Terajima H; Tada M; Adachi Y; Nishitai R; Manaka D; Yoshimura T; Doi K; Horimatsu T; Mitsuyoshi A; Yoshimura K; Niimi M; Matsumoto S; Sakai Y; Uemoto S
    Int J Clin Oncol; 2017 Apr; 22(2):316-323. PubMed ID: 27752787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001).
    Katayose Y; Yamamoto K; Nakagawal K; Takemura S; Takahashi M; Nakamura R; Shimamura H; Rikiyama T; Egawa S; Yoshda H; Motoi F; Naitoh T; Unno M
    Hepatogastroenterology; 2015; 62(138):303-8. PubMed ID: 25916054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
    BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
    Takatsuki M; Tokunaga S; Uchida S; Sakoda M; Shirabe K; Beppu T; Emi Y; Oki E; Ueno S; Eguchi S; Akagi Y; Ogata Y; Baba H; Natsugoe S; Maehara Y;
    Eur J Surg Oncol; 2016 Feb; 42(2):184-9. PubMed ID: 26683263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Matsumoto R; Kuroda T; Yamada H; Hasegawa K; Mamiya Y; Kon A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2207-9. PubMed ID: 20037372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
    Honjou H; Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2216-9. PubMed ID: 22202335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
    Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
    Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.